Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine

被引：22

作者：

Nakagawa, K ^{[1
]}

Ishizaki, T ^{[1
]}

机构：

[1] Kumamoto Univ, Grad Sch Clin Pharm, Dept Pharmacol & Therapeut, Kumamoto 8620973, Japan

来源：

PHARMACOLOGY & THERAPEUTICS | 2000年 / 86卷 / 01期

关键词：

pharmacogenetics; polymorphism; cytochromes P-450 (CYPs); cardiovascular drugs; cardiovascular diseases; pharmacodynamics;

D O I：

10.1016/S0163-7258(99)00066-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The variability in the individual response to drugs may be due either to interindividual variations in the pharmacokinetics of the drugs or to the heterogeneity of the mechanism(s) underlying the diseases, or both. In both cases, genetic heterogeneity is involved in the metabolism of cardiovascular drugs and pathogenesis of inherited cardiovascular disorders. Molecular genetic technologies can now provide sensitive and efficient genetic testing, not only to identify polymorphic drug metabolism genes, but also to identify disease-associated genes for diagnosis and risk stratification of many hereditary cardiovascular diseases. In this review, we discuss the polymorphic metabolism of cardiovascular drugs and the molecular genetics of cardiovascular diseases in relation to the genes determining the responsiveness to a given drug. (C) 2000 Elsevier Science Inc. All rights reserved.

引用

页码：1 / 28

页数：28

共 360 条

[1]

Ackerman M J, 1998, Pediatr Rev, V19, P232, DOI 10.1542/pir.19-7-232

[2] Mechanisms of disease - Ion channels - Basic science and clinical disease [J].

Ackerman, MJ ;

Clapham, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (22) :1575-1586

[3] ACE gene polymorphism: Ischemic heart disease and longevity in 10150 individuals - A case-referent and retrospective cohort study based on the Copenhagen City Heart Study [J].

AgerholmLarsen, B ;

Nordestgaard, BG ;

Steffensen, R ;

Sorensen, TIA ;

Jensen, G ;

TybjaergHansen, A .

CIRCULATION, 1997, 95 (10) :2358-2367

[4] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[5]

ALVAN G, 1982, LANCET, V1, P333

[6] INTERACTION OF BASE-LINE CHARACTERISTICS WITH THE HAZARD OF ENCAINIDE, FLECAINIDE, AND MORICIZINE THERAPY IN PATIENTS WITH MYOCARDIAL-INFARCTION - A POSSIBLE EXPLANATION FOR INCREASED MORTALITY IN THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL (CAST) [J].

ANDERSON, JL ;

PLATIA, EV ;

HALLSTROM, A ;

HENTHORN, RW ;

BUCKINGHAM, TA ;

CARLSON, MD ;

CARSON, PE .

CIRCULATION, 1994, 90 (06) :2843-2852

[7] Sulfation of minoxidil by multiple human cytosolic sulfotransferases [J].

Anderson, RJ ;

Kudlacek, PE ;

Clemens, DL .

CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 109 (1-3) :53-67

[8]

ANDRESEN BS, 1995, SCAND J CLIN LAB INV, V55, P9

[9]

[Anonymous], 1989, NEW ENGL J MED, V321, P406

[10] MULTIPLE PATHWAYS OF PROPRANOLOLS METABOLISM ARE INHIBITED BY DEBRISOQUIN [J].

ANTHONY, L ;

KOSHAKJI, R ;

WOOD, AJJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (03) :297-300

← 1 2 3 4 5 6 7 8 9 10 →